These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27055579)

  • 1. Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.
    Riches JC; Gribben JG
    Curr Cancer Drug Targets; 2016; 16(8):689-700. PubMed ID: 27055579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
    Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
    Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
    Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
    Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Gentile M; Recchia AG; Vigna E; Mazzone C; Lucia E; Gigliotti V; Bossio S; Madeo A; Morabito L; Servillo P; Franzese S; Caruso N; De Stefano L; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Feb; 20(2):273-86. PubMed ID: 21214505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of lenalidomide in chronic lymphocytic leukemia].
    Lei W; Zhou KS; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):565-8. PubMed ID: 24763044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide alone and in combination for chronic lymphocytic leukemia.
    Chen CI
    Curr Hematol Malig Rep; 2013 Mar; 8(1):7-13. PubMed ID: 23254517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.
    Maffei R; Fiorcari S; Bulgarelli J; Rizzotto L; Martinelli S; Rigolin GM; Debbia G; Castelli I; Bonacorsi G; Santachiara R; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
    Exp Hematol; 2014 Feb; 42(2):126-36.e1. PubMed ID: 24212063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
    Han TT; Fan L; Li JY; Xu W
    Cancer Biol Ther; 2014 Jan; 15(1):3-9. PubMed ID: 24149438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
    Desai AV; El-Bakkar H; Abdul-Hay M
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):314-22. PubMed ID: 25445466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation and immune reconstitution in chronic lymphocytic leukemia.
    Riches JC; Gribben JG
    Semin Hematol; 2014 Jul; 51(3):228-34. PubMed ID: 25048786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide in the treatment of chronic lymphocytic leukemia.
    Itchaki G; Brown JR
    Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
    Giannopoulos K; Mertens D; Stilgenbauer S
    Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide as first-line therapy for elderly CLL patients.
    Gilbert JA
    Lancet Oncol; 2013 Aug; 14(9):e345. PubMed ID: 24058966
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel agents for chronic lymphocytic leukemia.
    Wu M; Akinleye A; Zhu X
    J Hematol Oncol; 2013 May; 6():36. PubMed ID: 23680477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
    Maffei R; Fiorcari S; Martinelli S; Benatti S; Bulgarelli J; Rizzotto L; Debbia G; Santachiara R; Rigolin GM; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
    Leuk Lymphoma; 2018 Feb; 59(2):423-433. PubMed ID: 28639485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?
    Brown JR
    Leuk Lymphoma; 2010 Aug; 51(8):1382-5. PubMed ID: 20624030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.
    Molica S
    Leuk Lymphoma; 2007 May; 48(5):866-9. PubMed ID: 17487728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.
    Acebes-Huerta A; Huergo-Zapico L; Gonzalez-Rodriguez AP; Fernandez-Guizan A; Payer AR; López-Soto A; Gonzalez S
    Biomed Res Int; 2014; 2014():265840. PubMed ID: 25313353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
    Wiernik PH
    Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.